We are live on ! Find out more
BCM

Biomark Capital Management Portfolio holdings

AUM $8.9M
1-Year Est. Return 97.06%
This Fund
S&P 500
This Quarter Est. Return
+37.69%
1 Year Est. Return
+97.06%
3 Year Est. Return
+113.75%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$8.9M
AUM Growth
+$2.43M
Cap. Flow
$0
Cap. Flow %
0%
Top 10 Hldgs %
100%
Holding
2
New
–
Increased
–
Reduced
–
Closed
–

Top Buys

No buys this quarter

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ADMA icon
1
ADMA Biologics
ADMA
$1.96B
$8.9M 99.96%
1,433,304
– –
MBVX
2
DELISTED
MABVAX THERAPEUTICS HLDGS INC
MBVX
$4K 0.04%
8,903
– –

Similar funds

OBP
Old Bellows Partners New York $9.01M AUM 83.84% 1-Year Est. Return
HC
Highstar Capital New York $8.59M AUM 3.82% 1-Year Est. Return
SBA
Seven Bridges Advisors New York $9.75M AUM 16.73% 1-Year Est. Return
CIG
Candlewood Investment Group Rye, New York $10.1M AUM 30% 1-Year Est. Return
LRM
Lime Rock Management Westport, Connecticut $7.54M AUM 22.09% 1-Year Est. Return
IPLA
Ice Pond Lane Advisers New York $7.38M AUM 1.66% 1-Year Est. Return
GA
Glenhill Advisors New York $6.94M AUM 24.62% 1-Year Est. Return
CCM
Catalus Capital Management Greenwich, Connecticut $6.09M AUM 3.76% 1-Year Est. Return

Biomark Capital Management's Q3 2018 Portfolio in Review

As of Q3 2018, Biomark Capital Management held 2 positions worth $8.9M, up 38% from $6.47M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Trading was light in Q3 2018: portfolio turnover was 0%. Biomark Capital Management opened no new positions and made no exits, leaving the 2-position portfolio largely intact.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • Biomark Capital Management's ten largest holdings make up 100% of its $8.9M portfolio in Q3 2018.
  • Biomark Capital Management opened 0 new positions and closed 0 in Q3 2018.
  • Biomark Capital Management's portfolio value rose 38% quarter-over-quarter to $8.9M.

Based on Biomark Capital Management's 13F filing for Q3 2018, filed 24 Oct 2018.